T2 Biosystems Announces Director & Officer Changes
| Field | Detail |
|---|---|
| Company | T2 Biosystems, Inc. |
| Form Type | 8-K |
| Filed Date | Apr 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
T2 Biosystems shakes up its board and exec pay structure.
AI Summary
T2 Biosystems, Inc. announced on March 18, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate underlying issues or strategic realignments that may impact future performance.
Key Players & Entities
- T2 Biosystems, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- March 18, 2025 (date) — Date of earliest event reported
- 101 Hartwell Avenue, Lexington, Massachusetts 02421 (address) — Principal executive offices
FAQ
What specific reasons were given for the departure of certain officers or directors?
The filing states that it is reporting the 'Departure of Directors or Certain Officers' but does not provide specific reasons for these departures in the provided text.
Who are the newly elected directors?
The filing indicates the 'Election of Directors' but does not name the individuals elected in the provided text.
What are the details of the updated compensatory arrangements for officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' but does not specify the details of these arrangements in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 18, 2025.
What is T2 Biosystems, Inc.'s principal executive office address?
The principal executive office is located at 101 Hartwell Avenue, Lexington, Massachusetts 02421.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 regarding T2 Biosystems, Inc..